Society Roundtable Prioritizes Hypoglycemia

On April 29, the Society co-hosted a roundtable with Merck to discuss the current hypoglycemia landscape and to delve deeper into policy priorities that were identified at our diabetes policy summit last September. The roundtable featured key officials from professional societies, patient advocates, quality improvement organizations, and the federal government, including NIDDK, CDC, and Veteran’s Health Administration. At the meeting, participants discussed various perspectives on hypoglycemia as they relate to the patient experience, research and surveillance, issues in the clinical setting, and quality improvement.

The Society will continue working with Merck and participants at the roundtable on initiatives to increase awareness of hypoglycemia and identify areas for collaboration. Tony McCall, MD, PhD, Endocrine Society Vice President for Clinical Science, was our representative and did a masterful job distilling the issues and providing context for next steps. We will keep members apprised of the follow-up.

You may also like

  • August 2024 Endocrine Society Advocacy Update

    Revised Version of TROA Passes House Ways & Means Committee On June 27, 2024, the House Ways and Means Committee passed a revised version of the Treat and Reduce Obesity Act (TROA), legislation that would allow Medicare coverage of anti-obesity medications (AOMs), which currently is prohibited under law. The version that passed would only allow…

  • Endocrine Society Continues Global EDC Advocacy; EU Election Results Leaves Outcomes for EDC Legislation Uncertain  

    On June 17, the Endocrine Society joined delegations from dozens of countries gathered in Geneva, Switzerland, for the third session of an ad hoc open-ended working group (OEWG) convened under the United Nations Environment Programme (UNEP) to develop proposals to establish a new science policy panel charged with helping to inform governments, companies, farmers and…

Find more in